The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population
Abstract Objective To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system. Methods We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 20...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.52268 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592656060907520 |
|---|---|
| author | Aaron M. Carlson Carlos E.V. Sollero Andrew B. Wolf Stefan Sillau Barrie L. Schmitt Kelli M. Money Kavita V. Nair Amanda L. Piquet Jeffrey L. Bennett |
| author_facet | Aaron M. Carlson Carlos E.V. Sollero Andrew B. Wolf Stefan Sillau Barrie L. Schmitt Kelli M. Money Kavita V. Nair Amanda L. Piquet Jeffrey L. Bennett |
| author_sort | Aaron M. Carlson |
| collection | DOAJ |
| description | Abstract Objective To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system. Methods We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin‐4 IgG test or (2) any G36 ICD‐10 code. We extracted key clinical elements by chart review and confirmed diagnosis by the 2015 International Panel for NMO Diagnosis criteria. Annual incidence and prevalence rates were calculated. Results Our population consisted of 2,475,591 individuals contributing 11,103,522.72 person‐years of observation. In total, 115 seropositive NMOSD patients were identified. The average yearly incidence was 0.22 per 100,000 person‐years. Age and sex‐adjusted prevalence (per 100,000) was 4.33, and highest among those identifying as Asian or Pacific Islander (17.72), and Black (14.74), as separately by Hispanic ethnicity (8.02). Prevalence was higher in women (6.20:1 female:male ratio). Transverse myelitis (45%) and optic neuritis (43%) were the most common presenting clinical syndromes. In total, 6% of initial presentations were characterized by short‐segment transverse myelitis without other features. Interpretation Seropositive NMOSD incidence is higher in our cohort than many contemporary studies. Women and those identifying as Asian or Pacific Islander, Black, and Hispanic shoulder the highest burden of disease. Clinical onset with short‐segment myelitis underscores the need for serum aquaporin‐4 IgG testing in acute myelitis presentations. |
| format | Article |
| id | doaj-art-928ef036b63f4dd78fae5eedf459d0da |
| institution | Kabale University |
| issn | 2328-9503 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Clinical and Translational Neurology |
| spelling | doaj-art-928ef036b63f4dd78fae5eedf459d0da2025-01-21T05:41:42ZengWileyAnnals of Clinical and Translational Neurology2328-95032025-01-0112116917910.1002/acn3.52268The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US populationAaron M. Carlson0Carlos E.V. Sollero1Andrew B. Wolf2Stefan Sillau3Barrie L. Schmitt4Kelli M. Money5Kavita V. Nair6Amanda L. Piquet7Jeffrey L. Bennett8Department of Neurology University of Colorado School of Medicine Aurora Colorado USADepartment of Neurology University of Rochester Rochester New York USADepartment of Neurology University of Colorado School of Medicine Aurora Colorado USADepartment of Neurology University of Colorado School of Medicine Aurora Colorado USADepartment of Neurology University of Colorado School of Medicine Aurora Colorado USAUniversity of Colorado Health Memorial Hospital Colorado Springs Colorado USADepartment of Neurology University of Colorado School of Medicine Aurora Colorado USADepartment of Neurology University of Colorado School of Medicine Aurora Colorado USADepartments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, Anschutz Medical Campus University of Colorado School of Medicine Aurora Colorado USAAbstract Objective To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system. Methods We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin‐4 IgG test or (2) any G36 ICD‐10 code. We extracted key clinical elements by chart review and confirmed diagnosis by the 2015 International Panel for NMO Diagnosis criteria. Annual incidence and prevalence rates were calculated. Results Our population consisted of 2,475,591 individuals contributing 11,103,522.72 person‐years of observation. In total, 115 seropositive NMOSD patients were identified. The average yearly incidence was 0.22 per 100,000 person‐years. Age and sex‐adjusted prevalence (per 100,000) was 4.33, and highest among those identifying as Asian or Pacific Islander (17.72), and Black (14.74), as separately by Hispanic ethnicity (8.02). Prevalence was higher in women (6.20:1 female:male ratio). Transverse myelitis (45%) and optic neuritis (43%) were the most common presenting clinical syndromes. In total, 6% of initial presentations were characterized by short‐segment transverse myelitis without other features. Interpretation Seropositive NMOSD incidence is higher in our cohort than many contemporary studies. Women and those identifying as Asian or Pacific Islander, Black, and Hispanic shoulder the highest burden of disease. Clinical onset with short‐segment myelitis underscores the need for serum aquaporin‐4 IgG testing in acute myelitis presentations.https://doi.org/10.1002/acn3.52268 |
| spellingShingle | Aaron M. Carlson Carlos E.V. Sollero Andrew B. Wolf Stefan Sillau Barrie L. Schmitt Kelli M. Money Kavita V. Nair Amanda L. Piquet Jeffrey L. Bennett The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population Annals of Clinical and Translational Neurology |
| title | The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population |
| title_full | The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population |
| title_fullStr | The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population |
| title_full_unstemmed | The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population |
| title_short | The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population |
| title_sort | epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a us population |
| url | https://doi.org/10.1002/acn3.52268 |
| work_keys_str_mv | AT aaronmcarlson theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT carlosevsollero theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT andrewbwolf theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT stefansillau theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT barrielschmitt theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT kellimmoney theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT kavitavnair theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT amandalpiquet theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT jeffreylbennett theepidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT aaronmcarlson epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT carlosevsollero epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT andrewbwolf epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT stefansillau epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT barrielschmitt epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT kellimmoney epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT kavitavnair epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT amandalpiquet epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation AT jeffreylbennett epidemiologyandclinicalpresentationofseropositiveneuromyelitisopticaspectrumdisorderinauspopulation |